Dr. Beiki-Ardakani's areas of research interest include brachytherapy; MRI-guided brachytherapy for gynecological and prostate cancers; eye plaque therapy; fluid marker development for image-guided brachytherapy; and quality assurance and control.
Comparison of dosimetric parameters derived from whole organ and wall contours for bladder and rectum in cervical cancer patients treated with intracavitary and interstitial brachytherapy.
Radiother Oncol. 2018 Feb 06;:
Technique adaptation, strategic replanning, and team learning during implementation of MR-guided brachytherapy for cervical cancer.
Brachytherapy. 2018 Jan - Feb;17(1):86-93
Intermediate dose-volume parameters and the development of late rectal toxicity after MRI-guided brachytherapy for locally advanced cervix cancer.
Brachytherapy. 2017 Jul 27;:
Prospective Study of Dynamic Contrast-Enhanced MRI, Diffusion-Weighted MRI, and FDG Positron Emission Tomography Imaging in Brachytherapy for Cervix Cancer.
Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2S):E296
A prospective study of DWI, DCE-MRI and FDG PET imaging for target delineation in brachytherapy for cervical cancer.
Radiother Oncol. 2016 Aug 12;
Dosimetric and late radiation toxicity comparison between iodine-125 brachytherapy and stereotactic radiation therapy for juxtapapillary choroidal melanoma.
Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):510-5
A comparison between ¹²⁵Iodine brachytherapy and stereotactic radiotherapy in the management of juxtapapillary choroidal melanoma.
Br J Ophthalmol. 2013 Mar;97(3):327-32
Med Phys. 2008 Oct;35(10):4318-23
Med Phys. 2004 Jul;31(7):1960-3